COMMENTS: Part of the growing trend for big pharma to secure bid data
sources for their own use.
IMPACT: A move in the right direction towards ‘regulatory grade’ RWE,
READ TIME: 2 mins
1. “Target RWE, which provides real-world evidence (RWE) solutions to the
pharmaceutical and biotech industries has acquired NoviSci Inc., a software
analytics and services company.”
2. “Related to this acquisition, Amgen Inc., a strategic investor in and
collaborator with NoviSci, has also made a strategic investment in the
combined company to fuel growth, joining existing Target RWE investors
Norwest Venture Partners and 22C Capital.”
3. “NoviSci technology combined with Target RWE’s will make it possible
for doctors, researchers, and others to find and use solid, scientifically
rigorous analysis in a relatively digestible form that automatically
updates as new information is available.”
4. “The acquisition significantly broadens Target RWE’s data analytics
capabilities and will enable the company to meet increasing demand for
high-quality evidence from real-world data, the companies said.”
5. “Target RWE designs custom data sets, analyses, and evidence to address
the complexities of healthcare evidence questions and quality
initiatives.”
Source URL:
Biotech giant Amgen invests after Durham startups combine in healthcare data deal